These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26049403)

  • 1. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
    Bonnefond A; Yengo L; Le May C; Fumeron F; Marre M; Balkau B; Charpentier G; Franc S; Froguel P; Cariou B;
    Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.
    Awan Z; Delvin EE; Levy E; Genest J; Davignon J; Seidah NG; Baass A
    Can J Cardiol; 2013 Aug; 29(8):927-33. PubMed ID: 23743349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
    Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis.
    Liu S; Wan J; Wang D; Yang Y; Fang J; Luo T; Liang D; Hu J; Hou J; Wang P
    Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1339-1351. PubMed ID: 38734541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
    Noguchi T; Kobayashi J; Yagi K; Nohara A; Yamaaki N; Sugihara M; Ito N; Oka R; Kawashiri MA; Tada H; Takata M; Inazu A; Yamagishi M; Mabuchi H
    Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
    Chernogubova E; Strawbridge R; Mahdessian H; Mälarstig A; Krapivner S; Gigante B; Hellénius ML; de Faire U; Franco-Cereceda A; Syvänen AC; Troutt JS; Konrad RJ; Eriksson P; Hamsten A; van 't Hooft FM
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1526-34. PubMed ID: 22460556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
    Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
    Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.
    Saavedra YGL; Dufour R; Baass A
    J Clin Lipidol; 2015; 9(6):786-793.e1. PubMed ID: 26687699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
    Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.